Skip to main content
. 2018 Sep 22;82(6):971–978. doi: 10.1007/s00280-018-3687-4

Fig. 3.

Fig. 3

Simulated change from baseline in tumor size over 24 weeks for lenvatinib dosing regimens without up-titration (a) and with up-titration (b), and at 24 mg. Simulations were generated using the exposure–response model for time course in tumor size